Phase 2 Clinical Trial of ONC201 Mutation K27M defines distinct Glioma

Andrew Chi, MD, NYU Medical Oncology Associates Explains Phase 2 Clinical Trial of ONC201 Mutation K27M defines distinct Glioma in a Press Release.<br /> Author: Cancer-News Added: 03/20/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts